TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05732935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating intervention
Description: In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Successful Aging Comparison Group (LEARN)
Description: In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks.
Study: NCT05441683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontally extending incision
Description: An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Then horizontally extending incisions will be added to each side of the Intrasulcular incision, extending one to two teeth beyond the defected area, before a full-thickness flap is lifted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical releasing incision
Description: An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Vertical releasing incisions will be made on each side of the intrasulcular incision before a full-thickness flap is lifted.
Study: NCT06283810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy of interpersonal relationships
Description: Group KIPT will be 1 session per week and each session will last 90 minutes. There will be 7 sessions in total, and a completion session will be held 2 weeks after the completion of Group KIPT. In order for the students in G1 to understand which group they are in, they will also be informed about the points to be considered regarding laughter therapy. An unstructured laughter intervention will be applied at the beginning or at the end of the sessions in which group IPT is applied.~Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect). Within the scope of work packages 3 and 4, KIPT application and other measurements will be made.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter therapy
Description: Laughter therapy is 1 session per week and each session will last 40 minutes. A total of 8 sessions will continue. Each session will start with warm-up and deep breathing exercises and will continue with applause and childish games. Afterwards, games specific to each session will be added. Unstructured interviews will be conducted with G2 at the beginning or at the end of the session, suggesting that they were subjected to group CIPT. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect) when the interviews start.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo
Description: After the initial data are collected, unstructured interviews about the interpersonal relationships of the person will be conducted by conducting individual interviews with each student for 2-3 sessions at the beginning of the study in case the student does not understand which group he/she is in. Afterwards, unstructured random interviews and laughter intervention will be conducted for a total of 8 sessions lasting 40 minutes, 1 session per week. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week, 8th week and 12th week (long-term effect) when the interviews start.
Study: NCT06067100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and Mometasonefluroate (low dose)
Description: Participants are administered 125 µg indacaterol + mometasonefluroate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are administered placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and Mometasonefluroate (high dose)
Description: Participants are administered 500 µg indacaterol + mometasonefluroate
Study: NCT06017609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-861 Capsules
Description: Active drug capsules containing JTT-861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-861 Capsules
Description: Active drug capsules containing JTT-861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsules
Description: Placebo capsules matching in appearance to the active drug capsules
Study: NCT06401668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) strategy
Description: CHWs will offer participants personalized support to assist in overcoming barriers and leveraging facilitators to PRx uptake. CHWs are trained lay members of the communities they serve. The CHW strategy is an evidence-based.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRx Program
Description: The PRx Program provides free fruit and vegetables and nutrition education to patients with T2D and food insecurity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRx Program
Description: The PRx Program provides free fruit and vegetables and nutrition education to patients with T2D and food insecurity.
Study: NCT06649942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: KP-001 100 mg + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: KP-001 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: moxifloxacin 400 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04787549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality exergames
Description: A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
Study: NCT06497062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonrotoclax
Description: Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin/daunorubicin
Description: idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2, subcutaneously, once daily, on D1-7

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allo-HSCT
Description: Per standard of procedure
Study: NCT05834088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release techniques
Description: 12 treatment sessions will be given in 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release techniques
Description: 12 treatment sessions will be given in 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thiele massage
Description: 12 treatment sessions will be given in 12 weeks
Study: NCT05540340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan to determine the actual AUC achieved using the population PK.
Study: NCT06657352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACS Topical Treatment Group
Description: The topical group applied the ACS cream to the face twice daily (morning and night) for 4 weeks.
Study: NCT05767658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Brain Development and Parent-Child Relationships
Description: Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for early brain development and parent-child interactions (control intervention) and b) an online community and social network of other pregnant WIC clients and new parents.
Study: NCT05732831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG462
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG462
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG462
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally
Study: NCT03834818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPAS Participants
Description: The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~* Download the Medable App~* Register to the study~* Validated Questionnaires~* Active Task~Every Day~* 9:00 a.m. Daily Questions~* 9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~* Day 1 Pre-Surgery~* 1-Week Post Operation~* 2-Weeks Post Operation~* 1-Month Post Operation~* 3-Months Post Operation~* 6-Months Post Operation
Study: NCT05009069

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
Study: NCT06657352

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo Group
Description: The topical group applied the cream (without ACS) to the face twice daily (morning and night) for 4 weeks.
Study: NCT05732831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG462
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG462
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG462
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG462
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally
Study: NCT06657352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Treatment + Topical Treatment Group
Description: The combination group used both the topical and oral ACS products for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACS Oral Treatment Group
Description: The oral group ingested one ACS capsule twice daily after breakfast and dinner for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Group
Description: The oral group ingested one capsule (without ACS) twice daily after breakfast and dinner for 12 weeks.
Study: NCT05732831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An anti PD-1 antibody, will be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An anti PD-1 antibody, will be administered intravenously
Study: NCT06657352

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Treatment + Topical Placebo Group
Description: The combination group used both the topical and oral products without ACS for 12 weeks.
Study: NCT06408181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162 mg
Description: Aspirin is a nonsteroidal anti-inflammatory drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin 81mg
Description: Aspirin is a nonsteroidal anti-inflammatory drug.
Study: NCT05869773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP258
Description: 0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
Study: NCT06029257

Intervention type: DRUG
Intervention: Tildrakizumab
Description: As provided in real-world clinical practice.
Study: NCT06605651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution
Description: Three intra-articular injections during and/or following DAIR procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: Three intra-articular injections during and/or following DAIR procedure
Study: NCT06657651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement with dentin-derived membrane
Description: immediate implant placement with dentin-derived membrane and allograft in mandibular molar area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant with extended platelet rich fibrin membrane
Description: immediate implant with extended platelet rich fibrin membrane and allograft in mandibular molar area
Study: NCT06662240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The effect of vibration anesthesia on pain, ecchymosis and comfort level in subcutaneous heparin injection
Description: The patient in the experimental group received one vibrating injection and one non-vibrating injection into the abdomen. The patient in the control group received 2 standard subcutaneous injections in the abdomen without vibration.
Study: NCT06660875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block
Description: Serratus posterior superior intercostal plane block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block and superficial cervical plexus block
Description: İnterscalene brachial plexus block and superficial cervical plexus block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
Study: NCT06661239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: benson relaxation
Description: The benson relaxation consisted of the following steps: (1) Sitting or lying down quietly in a comfortable position; (2) Closing eyes; (3) Deeply relaxing all muscles, beginning at the feet and progressing up to the face. Keeping them relaxed; (4) Breathing through the nose. (5) Maintaining a passive attitude and permitting relaxation to occur at its own pace; (6) Continuing for 15 minutes. When finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. Do not stand up for a few minutes.~According to the agreement, the patients in both groups were required to perform the Benson relaxation technique regularly twice daily (morning and evening) for seven days in a row. Each session lasted 15 minutes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine care in unit
Description: The routine care include in the unit will be delivered to control group
Study: NCT06660199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-based intervention
Description: Parents randomized to the texting intervention will receive up to 3 messages each day for 6 weeks: The intervention is comprised of adolescent-centered (A-C) texts focusing on parental adherence to recommended suicide prevention strategies to promote adolescents' safety and parent-centered (P-C) texts focused on improving parents' own well-being.
Study: NCT06588530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TENIVAC
Description: TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) is an active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
Study: NCT05362773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD024
Description: MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
Study: NCT04923542

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
Study: NCT06611345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: Tumor treating fields will be used each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
Study: NCT04923542

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
Study: NCT06068543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-Gallate (EGCG)
Description: 800mg Epigallocatechin-3-Gallate (EGCG)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose (MCC)
Description: 800mg microcrystalline cellulose (MCC)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (Vitamin C)
Description: 250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid (Vitamin C)
Description: 250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks
Study: NCT06543732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Return to work program
Description: The eHealth modules focus on psychoeducation, perceptions of return to work based on a personal plan including problem-solving exercises, relapse prevention, and continuous monitoring. If needed, followed by the participatory approach, a stepwise, collaborative approach to analyse and solve bottlenecks to develop a consensus-based plan for return to work.
Study: NCT06063434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night Shift
Description: The player must not only manage the patients who present to the emergency department of the hospital, gaining experience with the consequences of trauma triage, but also solve the mystery of the grandfather, gaining an emotional connection with the character and making the feedback that Andy receives more relevant. Embedded within Night Shift 2024 is a mini-game (Graveyard Shift) that contains a series of puzzles that reinforce the lessons of the overarching game: transfer severely injured patients expeditiously.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual education
Description: Standard continuing medical education, including Advanced Trauma Life Support, and the American Board of Emergency Medicine educational modules (e.g., trauma resuscitation).